Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin after initiation of androgen deprivation therapy for metastatic prostate cancer
2016-004774-17Phase 3Active
- Sponsor
- Pirkanmaa Hospital District
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) and Metastatic Prostate Cancer (mPC) comparing Atorvastatin plus androgen deprivation therapy with Placebo plus androgen deprivation therapy (2 arms). Primary endpoint: Development of castration resistance during androgen deprivation therapy. Started Aug 2018; status: active.
02
Drugs
atorvastatin
03
Conditions
prostate cancer (PCa)Metastatic Prostate Cancer (mPC)
Beyond the preview
Go deeper on 2016-004774-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004774-17.